YZYulia V. Zabutova

Yulia V. Zabutova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yulia V. Zabutova has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Secondary haemophagocytic lymphohistiocytosis in blood malignancies. The multicentre retrospective study

    by Vsevolod G. Potapenko, Alina S. Antipova, Julia A. Zhuravleva, Yulia V. Zabutova, Alina Yu. Zavyalova, Irina V. Ishmatova, Elena V. Karyagina, Natalia A. Kotova, Valeria V. Kozyro, Tatiana G. Kulibaba, et al.

    Haemophagocytic syndrome (HPS) or haemophagocytic lymphohistiocytosis is a reaction of severe but ineffective inflammation. Blood malignancies (BlM) are among the frequent causes of HPS in adults. Objective. To analyse survival, causing trigger haemoblastosis, relationship with tumor and efficacy of including etoposide in chemotherapy of patients with secondary HPS-BlM. Material and methods. A retrospective analysis of case histories of patients with BlM complicated by SHPS was performed. The diagnosis of SHPS was verified using H-score and HLH-2004 criteria. Patients with both active malignant process and response to treatment were included in the study. Results. A total of 66 patients, median age 64 (19–90) years, 26 males and 40 females were included in the analysis. Of these, 44 (66.7%) had an active malignant process present. Overall survival in the SHPS-BlM group was 15.1% with a median of 2 (0.2–150) weeks. The prognosis was better in the group treated with etoposide than without it: three-week overall survival was 65.6% (n = 9) and 35%, respectively (p = 0.023). Median survival in the etoposide-free group was 1 (0.2–140) weeks. There were no diff erences in long-term survival depending on the presence of etoposide as part of chemotherapy. In patients without malignancy progression, a possible cause of SHPS was identified in only 8 (36.3%) patients. The overall survival rate was 18.1%, median 12 days (from 3 days to 150 weeks). Conclusion. The structure of patients with SHPS-BlM is dominated by patients with diff use B-cell large cell lymphoma. In the majority of patients SHPS is associated with progression, but in some patients VGFS activity persists despite the achievement of antitumour response. Inclusion of etoposide in therapy leads to an improved prognosis.

  • Open Access

    Возможности терапии хронической активной болезни и вторичного гемофагоцитарного синдрома, ассоциированных с вирусом Эпштейна—Барр (серия клинических наблюдений)

    by Всеволод Геннадьевич Потапенко, М. М. Антонов, Д. Д. Авдошина, М. М. Аксенова, В. В. Байков, М. Б. Белогурова, И. А. Бехтерева, Л. В. Глыжина, Э. Н. Дулаева, Ю. В. Забутова, et al.

    Epstein-Barr virus (EBV) infection is characterized by a benign course except for the rare variants which include chronic active disease (EBV-CAD) and secondary hemophagocytic syndrome (EBV-sHPS). sHPS is a life-threatening disorder associated with severely impaired immune response regulation. The pathogenesis is based on the activation of cytotoxic Т-lymphocytes, NK-cells and macrophages with overproduction of proinflammatory cytokines and ineffective systemic inflammatory response. The most common manifestations are persistent febrile fever, moderate cytopenia, cytolytic and cholestatic syndromes, and multiple organ failure. One of the most effective agents for the control of hyperergic reaction is etoposide. The present paper reports the outcomes of treating 5 EBV-sHPS patients and 1 EBV-CAD patient. All of them showed fever, liver dysfunction, hypofibrinogenemia, and cytopenia. In sHPS patients, pronounced hyperferritinemia was identified. At the time of submitting the present paper, 3 patients with no evident disease were still followed up.

  • Open Access

    Treatment of secondary hemophagocytic syndrome

    by V Potapenko, М Antonov, A Antipova, D Avdoshina, I Gaidukova, O Goloshchapov, E Dulaeva, Yu. Zabutova, E Karyagina, N Kotova, et al.

    Introduction. Hemophagocytic syndrome (HPS) is a reaction of severe, excessive, but ineffective inflammation. HPS is divided into primary or as a complication of a different causes — secondary HPS (sHPS).Aim: to analyze the effi cacy of different treatments in sHPS patients.Materials and methods. For the retrospective analysis, the medical documentation of patients who were treated in the period from June 2009 to January 2023 was used. The H-Score and HLH-2004 criteria were used to verify sHPS. The results of clinical blood analysis and biochemical tests are presented. The survival was analyzed within two weeks after the verification of sHPS. The main treatment options for sHPS were etoposide, glucocorticosteroids (GCSs), anticancer therapy and intravenous immunoglobulin.Results. The study included data from 130 patients, median age 56 years (18–90); 70 females and 60 males with sHPS. All patients received treatment with a drug change in cases of inefficiency: a total of 186 episodes. A stable response was achieved in 74 (56.9 %) patients. The median survival in patients without a response was 2 days. If the therapy was effective, the median survival was not reached. Positive dynamics were observed during the first day after the start of effective treatment, however, a few patients had transient worsening of some markers. The main factor in the negative prognosis was the degree of multiple organ failure during sHPS verification. In the group of patients with autoimmune diseases, GCSs were the most effective, with a response reached in 75 % of cases. For patients with resistance, as well as in patients with Epstein—Barr virus infection and blood malignancy, etoposide proved to be effective in 65.7 % of cases.Conclusion. sHPS was accompanied by an increase in pancytopenia, cytolytic, cholestatic syndromes, hypocoagulation, azotemia, hypertriglyceridemia and excessive hyperferritinemia. After the initiation of effective therapy, persistent clinical and laboratory responses developed during the first day. Therapy by GCSs was effective in most patients with autoimmune diseases associated with sHPS. With other forms of sHPS in the studied group, etoposide had the most pronounced effect.